TY  - JOUR
AU  - Labadie, Julia D
AU  - Harrison, Tabitha A
AU  - Banbury, Barbara
AU  - Amtay, Efrat L
AU  - Bernd, Sonja
AU  - Brenner, Hermann
AU  - Buchanan, Daniel D
AU  - Campbell, Peter T
AU  - Cao, Yin
AU  - Chan, Andrew T
AU  - Chang-Claude, Jenny
AU  - English, Dallas
AU  - Figueiredo, Jane C
AU  - Gallinger, Steven J
AU  - Giles, Graham G
AU  - Gunter, Marc J
AU  - Hoffmeister, Michael
AU  - Hsu, Li
AU  - Jenkins, Mark A
AU  - Lin, Yi
AU  - Milne, Roger L
AU  - Moreno, Victor
AU  - Murphy, Neil
AU  - Ogino, Shuji
AU  - Phipps, Amanda I
AU  - Sakoda, Lori C
AU  - Slattery, Martha L
AU  - Southey, Melissa C
AU  - Sun, Wei
AU  - Thibodeau, Stephen N
AU  - Van Guelpen, Bethany
AU  - Zaidi, Syed H
AU  - Peters, Ulrike
AU  - Newcomb, Polly A
TI  - Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location.
JO  - JNCI cancer spectrum
VL  - 4
IS  - 5
SN  - 2515-5091
CY  - Oxford
PB  - Oxford University Press
M1  - DKFZ-2020-01862
SP  - pkaa042
PY  - 2020
AB  - Postmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor location.We pooled data on tumor subtypes (microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, pathway: adenoma-carcinoma, alternate, serrated), tumor location (proximal colon, distal colon, rectum), and HT use among 8220 postmenopausal women (3898 CRC cases and 4322 controls) from 8 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95
LB  - PUB:(DE-HGF)16
C6  - pmid:32923935
C2  - pmc:PMC7477374
DO  - DOI:10.1093/jncics/pkaa042
UR  - https://inrepo02.dkfz.de/record/163159
ER  -